Telix Pharmaceuticals (TLX) Shares Outstanding (Weighted Average) (2023 - 2025)
Telix Pharmaceuticals (TLX) posted Shares Outstanding (Weighted Average) of $480.0 million for Q4 2025, up 119.27% on a QoQ basis from $218.9 million in Q4 2024, and up 119.27% year-over-year from $218.9 million in Q4 2024.
Telix Pharmaceuticals (TLX) has 3 years of Shares Outstanding (Weighted Average) data on file, last reported at $480.0 million in Q4 2025.
- In Q4 2025, Shares Outstanding (Weighted Average) rose 119.27% year-over-year to $480.0 million; the TTM figure through Dec 2025 stood at $480.0 million (up 119.27% YoY), while the FY2025 annual figure was $480.0 million, up 15.93% from the prior year.
- Shares Outstanding (Weighted Average) rose to $480.0 million in Q4 2025, from $218.9 million in the prior quarter.
- Across five years, Shares Outstanding (Weighted Average) topped out at $480.0 million in Q4 2025 and bottomed at $210.7 million in Q4 2023.
- A 3-year average of $303.2 million and a median of $218.9 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) climbed 3.87% — and 2025, when it surged 119.27%.
- Year by year, Shares Outstanding (Weighted Average) stood at $210.7 million in 2023, then rose by 3.87% to $218.9 million in 2024, then surged by 119.27% to $480.0 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $480.0 million (Q4 2025), $218.9 million (Q4 2024), and $210.7 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Telix Pharmaceuticals | 4.52 Bn | 4.38 Bn | - | 479.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 479.96 Mn |
| Dec 31, 2024 | 218.90 Mn |
| Dec 31, 2023 | 210.74 Mn |